Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
31,889
archived clinical trials in
Blood Cancer

Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated:  3/20/2018
NorthShore University HealthSystem-Evanston Hospital
mi
from
Evanston, IL
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated: 3/20/2018
NorthShore University HealthSystem-Evanston Hospital
mi
from
Evanston, IL
Click here to add this to my saved trials
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated:  3/20/2018
Galesburg Cottage Hospital
mi
from
Galesburg, IL
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated: 3/20/2018
Galesburg Cottage Hospital
mi
from
Galesburg, IL
Click here to add this to my saved trials
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated:  3/20/2018
Illinois CancerCare - Galesburg
mi
from
Galesburg, IL
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated: 3/20/2018
Illinois CancerCare - Galesburg
mi
from
Galesburg, IL
Click here to add this to my saved trials
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated:  3/20/2018
Western Illinois Cancer Treatment Center
mi
from
Galesburg, IL
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated: 3/20/2018
Western Illinois Cancer Treatment Center
mi
from
Galesburg, IL
Click here to add this to my saved trials
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated:  3/20/2018
Mason District Hospital
mi
from
Havana, IL
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated: 3/20/2018
Mason District Hospital
mi
from
Havana, IL
Click here to add this to my saved trials
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated:  3/20/2018
Hopedale Medical Complex - Hospital
mi
from
Hopedale, IL
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated: 3/20/2018
Hopedale Medical Complex - Hospital
mi
from
Hopedale, IL
Click here to add this to my saved trials
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated:  3/20/2018
Midwest Center for Hematology/Oncology
mi
from
Joliet, IL
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated: 3/20/2018
Midwest Center for Hematology/Oncology
mi
from
Joliet, IL
Click here to add this to my saved trials
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated:  3/20/2018
Joliet Oncology-Hematology Associates Limited
mi
from
Joliet, IL
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated: 3/20/2018
Joliet Oncology-Hematology Associates Limited
mi
from
Joliet, IL
Click here to add this to my saved trials
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated:  3/20/2018
Kewanee Hospital
mi
from
Kewanee, IL
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated: 3/20/2018
Kewanee Hospital
mi
from
Kewanee, IL
Click here to add this to my saved trials
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated:  3/20/2018
Deerpath Medical Associates
mi
from
Lake Forest, IL
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated: 3/20/2018
Deerpath Medical Associates
mi
from
Lake Forest, IL
Click here to add this to my saved trials
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated:  3/20/2018
McDonough District Hospital
mi
from
Macomb, IL
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated: 3/20/2018
McDonough District Hospital
mi
from
Macomb, IL
Click here to add this to my saved trials
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated:  3/20/2018
Loyola University Medical Center
mi
from
Maywood, IL
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated: 3/20/2018
Loyola University Medical Center
mi
from
Maywood, IL
Click here to add this to my saved trials
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated:  3/20/2018
Illinois Cancer Specialists-Niles
mi
from
Niles, IL
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated: 3/20/2018
Illinois Cancer Specialists-Niles
mi
from
Niles, IL
Click here to add this to my saved trials
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated:  3/20/2018
BroMenn Regional Medical Center
mi
from
Normal, IL
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated: 3/20/2018
BroMenn Regional Medical Center
mi
from
Normal, IL
Click here to add this to my saved trials
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated:  3/20/2018
Community Cancer Center Foundation
mi
from
Normal, IL
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated: 3/20/2018
Community Cancer Center Foundation
mi
from
Normal, IL
Click here to add this to my saved trials
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated:  3/20/2018
Illinois CancerCare-Ottawa Clinic
mi
from
Ottawa, IL
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated: 3/20/2018
Illinois CancerCare-Ottawa Clinic
mi
from
Ottawa, IL
Click here to add this to my saved trials
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated:  3/20/2018
Ottawa Regional Hospital and Healthcare Center
mi
from
Ottawa, IL
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated: 3/20/2018
Ottawa Regional Hospital and Healthcare Center
mi
from
Ottawa, IL
Click here to add this to my saved trials
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated:  3/20/2018
Pekin Hospital
mi
from
Pekin, IL
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated: 3/20/2018
Pekin Hospital
mi
from
Pekin, IL
Click here to add this to my saved trials
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated:  3/20/2018
Methodist Medical Center of Illinois
mi
from
Peoria, IL
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated: 3/20/2018
Methodist Medical Center of Illinois
mi
from
Peoria, IL
Click here to add this to my saved trials
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated:  3/20/2018
Proctor Hospital
mi
from
Peoria, IL
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated: 3/20/2018
Proctor Hospital
mi
from
Peoria, IL
Click here to add this to my saved trials
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated:  3/20/2018
Illinois CancerCare-Peoria
mi
from
Peoria, IL
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated: 3/20/2018
Illinois CancerCare-Peoria
mi
from
Peoria, IL
Click here to add this to my saved trials
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated:  3/20/2018
OSF Saint Francis Medical Center
mi
from
Peoria, IL
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated: 3/20/2018
OSF Saint Francis Medical Center
mi
from
Peoria, IL
Click here to add this to my saved trials
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated:  3/20/2018
Illinois Valley Hospital
mi
from
Peru, IL
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated: 3/20/2018
Illinois Valley Hospital
mi
from
Peru, IL
Click here to add this to my saved trials
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated:  3/20/2018
Valley Radiation Oncology
mi
from
Peru, IL
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated: 3/20/2018
Valley Radiation Oncology
mi
from
Peru, IL
Click here to add this to my saved trials
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated:  3/20/2018
Perry Memorial Hospital
mi
from
Princeton, IL
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated: 3/20/2018
Perry Memorial Hospital
mi
from
Princeton, IL
Click here to add this to my saved trials
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated:  3/20/2018
Sarah Culbertson Memorial Hospital
mi
from
Rushville, IL
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated: 3/20/2018
Sarah Culbertson Memorial Hospital
mi
from
Rushville, IL
Click here to add this to my saved trials
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated:  3/20/2018
Edward H. Kaplan, M.D. & Associates
mi
from
Skokie, IL
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated: 3/20/2018
Edward H. Kaplan, M.D. & Associates
mi
from
Skokie, IL
Click here to add this to my saved trials
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated:  3/20/2018
Hematology Oncology Associates of Illinois
mi
from
Skokie, IL
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated: 3/20/2018
Hematology Oncology Associates of Illinois
mi
from
Skokie, IL
Click here to add this to my saved trials
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated:  3/20/2018
Midwest Cancer Research Group, Incorporated
mi
from
Skokie, IL
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated: 3/20/2018
Midwest Cancer Research Group, Incorporated
mi
from
Skokie, IL
Click here to add this to my saved trials
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated:  3/20/2018
Saint Margaret's Hospital
mi
from
Spring Valley, IL
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated: 3/20/2018
Saint Margaret's Hospital
mi
from
Spring Valley, IL
Click here to add this to my saved trials
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated:  3/20/2018
Memorial Medical Center
mi
from
Springfield, IL
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated: 3/20/2018
Memorial Medical Center
mi
from
Springfield, IL
Click here to add this to my saved trials
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated:  3/20/2018
Elkhart General Hospital
mi
from
Elkhart, IN
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated: 3/20/2018
Elkhart General Hospital
mi
from
Elkhart, IN
Click here to add this to my saved trials
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated:  3/20/2018
Community Howard Regional Health
mi
from
Kokomo, IN
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated: 3/20/2018
Community Howard Regional Health
mi
from
Kokomo, IN
Click here to add this to my saved trials
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated:  3/20/2018
IU Health La Porte Hospital
mi
from
La Porte, IN
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated: 3/20/2018
IU Health La Porte Hospital
mi
from
La Porte, IN
Click here to add this to my saved trials
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated:  3/20/2018
Saint Joseph Regional Medical Center-Mishawaka
mi
from
Mishawaka, IN
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated: 3/20/2018
Saint Joseph Regional Medical Center-Mishawaka
mi
from
Mishawaka, IN
Click here to add this to my saved trials
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated:  3/20/2018
Memorial Hospital of South Bend
mi
from
South Bend, IN
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated: 3/20/2018
Memorial Hospital of South Bend
mi
from
South Bend, IN
Click here to add this to my saved trials
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated:  3/20/2018
Northern Indiana Cancer Research Consortium
mi
from
South Bend, IN
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated: 3/20/2018
Northern Indiana Cancer Research Consortium
mi
from
South Bend, IN
Click here to add this to my saved trials
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated:  3/20/2018
McFarland Clinic PC-William R Bliss Cancer Center
mi
from
Ames, IA
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated: 3/20/2018
McFarland Clinic PC-William R Bliss Cancer Center
mi
from
Ames, IA
Click here to add this to my saved trials
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated:  3/20/2018
Medical Oncology and Hematology Associates-West Des Moines
mi
from
Clive, IA
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated: 3/20/2018
Medical Oncology and Hematology Associates-West Des Moines
mi
from
Clive, IA
Click here to add this to my saved trials
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated:  3/20/2018
Genesis Medical Center - East Campus
mi
from
Davenport, IA
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated: 3/20/2018
Genesis Medical Center - East Campus
mi
from
Davenport, IA
Click here to add this to my saved trials
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated:  3/20/2018
Genesis Medical Center - West Campus
mi
from
Davenport, IA
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated: 3/20/2018
Genesis Medical Center - West Campus
mi
from
Davenport, IA
Click here to add this to my saved trials
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated:  3/20/2018
Mercy Capitol
mi
from
Des Moines, IA
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated: 3/20/2018
Mercy Capitol
mi
from
Des Moines, IA
Click here to add this to my saved trials
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated:  3/20/2018
Iowa Methodist Medical Center
mi
from
Des Moines, IA
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated: 3/20/2018
Iowa Methodist Medical Center
mi
from
Des Moines, IA
Click here to add this to my saved trials
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated:  3/20/2018
Medical Oncology and Hematology Associates-Des Moines
mi
from
Des Moines, IA
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated: 3/20/2018
Medical Oncology and Hematology Associates-Des Moines
mi
from
Des Moines, IA
Click here to add this to my saved trials
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated:  3/20/2018
Medical Oncology and Hematology Associates-Laurel
mi
from
Des Moines, IA
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated: 3/20/2018
Medical Oncology and Hematology Associates-Laurel
mi
from
Des Moines, IA
Click here to add this to my saved trials
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated:  3/20/2018
Mercy Medical Center - Des Moines
mi
from
Des Moines, IA
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated: 3/20/2018
Mercy Medical Center - Des Moines
mi
from
Des Moines, IA
Click here to add this to my saved trials
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated:  3/20/2018
Iowa Lutheran Hospital
mi
from
Des Moines, IA
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated: 3/20/2018
Iowa Lutheran Hospital
mi
from
Des Moines, IA
Click here to add this to my saved trials
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated:  3/20/2018
Siouxland Regional Cancer Center
mi
from
Sioux City, IA
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated: 3/20/2018
Siouxland Regional Cancer Center
mi
from
Sioux City, IA
Click here to add this to my saved trials
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated:  3/20/2018
Mercy Medical Center - Sioux City
mi
from
Sioux City, IA
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated: 3/20/2018
Mercy Medical Center - Sioux City
mi
from
Sioux City, IA
Click here to add this to my saved trials
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated:  3/20/2018
Saint Luke's Regional Medical Center
mi
from
Sioux City, IA
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated: 3/20/2018
Saint Luke's Regional Medical Center
mi
from
Sioux City, IA
Click here to add this to my saved trials